EHA 2023 | Final results of ALLG ALL08: blinatumomab with reduced intensity chemo in older adults with B-ALL
Shaun Fleming, MBBS, FRACP, FRCPA, Alfred Hospital, Melbourne, Australia, shares the final results of the ALLG ALL08 study (ACTRN12617000084381) assessing sequential blinatumomab with reduced intensity chemotherapy in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL). While the study did not meet its primary endpoint, this treatment was well tolerated and was associated with a high rate of complete remissions (CR), deep measurable residual disease (MRD) responses, and encouraging overall survival (OS) and event-free survival (EFS) results. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen – research funding, speakers honoraria, advisory board membership
Gilead – advisory board membership
Novartis – speakers honorarium
BMS – advisory board membership, speakers honorarium
Pfizer – advisory board membership, speakers honorarium
